
|Articles|October 1, 2003
No Quick-Fix Solution
New York - While the micronized formulation of Alloderm (Cymetra, LifeCell Corp.) is an appropriate substance for correcting certain facial defects, the physician who wants to use it may need to manage patient expectations, according to Anthony P. Sclafani, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















